falsefalse

Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC) - Episode 5

Management of Borderline Resectable NSCLC

, , ,

The panel discusses reassessing for respectability after certain treatments.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%
    EP. 2: Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC
    EP. 3: Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC
    EP. 4: Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC
    Now Viewing
    EP. 5: Management of Borderline Resectable NSCLC
    EP. 6: Management of Resectable Early Stage NSCLC with Actionable Mutations
    EP. 7: Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC
    EP. 8: Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease
    EP. 9: Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC
    EP. 10: Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

    Video content above is prompted by the following:

    In patients deemed borderline resectable, do you re-assess for resectability after neoadjuvant chemoimmunotherapy?

    • How do you manage patients who do not undergo surgery after neoadjuvant chemoimmunotherapy?
    • How do you managepatientswho do not achieve a pCR or an MPR after neoadjuvant chemo-IO?

    How do you manage patients who do not achieve a pCR or an MPR after neoadjuvant

    x